A38 Lactobacillus paracasei ssp. paracasei F-19 and intestinal failure: use in stage 1 of necrotising enterocolitis (NEC)

Zampieri, Nicola; Camoglio, Francesco Saverio; Scirè, G.; Laconi, F.; Pietrobelli, Angelo

doi:10.1016/s0378-3782(12)70064-6

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the LAB, Lactobacillus paracasei ( L. paracasei ) has great potential as an antigen delivery host. Studies have shown that L. paracasei can persist in intestinal and vaginal tissues, as well as reduce the presence of pathogenic Escherichia coli and Shigella in the human intestinal microflora (Zampieri et al 2012 ). Muhammed et al utilized L. paracasei (DUP-13076; LP), Lactobacillus rhamnosus (nrrlb442; LR), and Lactobacillus delbrueckii subsp.…”

Section: Introductionmentioning

confidence: 99%

Assessing immunogenicity of CRISPR-NCas9 engineered strain against porcine epidemic diarrhea virus

Li,

Zhao,

Sui

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Porcine epidemic diarrhea (PED) caused by porcine epidemic diarrhea virus (PEDV), is an acute and highly infectious disease, resulting in substantial economic losses in the pig industry. Given that PEDV primarily infects the mucosal surfaces of the intestinal tract, it is crucial to improve the mucosal immunity to prevent viral invasion. Lactic acid bacteria (LAB) oral vaccines offer unique advantages and potential applications in combatting mucosal infectious diseases, making them an ideal approach for controlling PED outbreaks. However, traditional LAB oral vaccines use plasmids for exogenous protein expression and antibiotic genes as selection markers. Antibiotic genes can be diffused through transposition, transfer, or homologous recombination, resulting in the generation of drug-resistant strains. To overcome these issues, genome-editing technology has been developed to achieve gene expression in LAB genomes. In this study, we used the CRISPR-NCas9 system to integrate the PEDV S1 gene into the genome of alanine racemase-deficient Lactobacillus paracasei △Alr HLJ-27 (L. paracasei △Alr HLJ-27) at the thymidylate synthase (thyA) site, generating a strain, S1/△Alr HLJ-27. We conducted immunization assays in mice and piglets to evaluate the level of immune response and evaluated its protective effect against PEDV through challenge tests in piglets. Oral administration of the strain S1/△Alr HLJ-27 in mice and piglets elicited mucosal, humoral, and cellular immune responses. The strain also exhibited a certain level of resistance against PEDV infection in piglets. These results demonstrate the potential of S1/△Alr HLJ-27 as an oral vaccine candidate for PEDV control. Key points • A strain S1/△Alr HLJ-27 was constructed as the candidate for an oral vaccine. • Immunogenicity response and challenge test was carried out to analyze the ability of the strain. • The strain S1/△Alr HLJ-27 could provide protection for piglets to a certain extent.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessing immunogenicity of CRISPR-NCas9 engineered strain against porcine epidemic diarrhea virus

Li,

Zhao,

Sui

et al. 2024

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…It is possible that diet-related factors including alterations of the microbiota may have a role in determining or worsening EC. In this instance, it has been shown that probiotic supplementation contributes to eosinophil trafficking and inflammation in the colon [ 24 , 25 ]. In our series, we could not retrieve precise data about the dietary habits and the socioeconomic status, and hence more studies are needed in this regard.…”

Section: Discussionmentioning

confidence: 99%

Clinical and atopic features of patients with primary eosinophilic colitis: an Italian multicentre study

Rossi,

Lenti,

Merli

et al. 2024

Intern Emerg Med

View full text Add to dashboard Cite

Eosinophilic colitis (EC) is the rarest among primary eosinophilic gastrointestinal disorders (EGID). EC is underdiagnosed due to its blurred and proteiform clinical manifestations. To explore the clinical and atopic characteristic of EC adult patients, the diagnostic delay, and relapse-associated factors, by comparison with patients with eosinophilic esophagitis (EoE) and irritable bowel syndrome (IBS). EC patients followed-up at four clinics were included, and clinical, histopathological, and laboratory data were retrieved. As control groups, age-matched patients with EoE and IBS were recruited. Allergy tests included skin prick test and serum specific IgE. Diagnostic delay was assessed. Overall, data from 73 patients were retrieved, including 40 with EC (median age 39 years IQR 22.5–59, F:M 2.1:1), 12 with EoE (F:M ratio: 1:5), and 21 with IBS (F:M ratio: 1:0.9). The most common features in EC patients were female sex (67.5%), atopy (77.5%), abdominal pain/distention (70%), diarrhoea (77.5%), and faecal calprotectin elevation (22.5%). Blood eosinophils were elevated in EoE, but not in EC (p < 0.001), while ECP did not differ across the three groups (p = 0.4). The frequency of allergen sensitization reached 25% of patients. Several frequent pan-allergens for this region were present. The overall diagnostic delay was 10 months (IQR 4–15). Factors contributing to a greater diagnostic delay were atopy, weight loss, and a previous misdiagnosis. EC is mostly a diagnosis of exclusion, burdened by a substantial diagnostic delay. In female patients the presence of allergen sensitization, abdominal symptoms and faecal calprotectin elevation should raise the suspicion of EC.

show abstract

A38 Lactobacillus paracasei ssp. paracasei F-19 and intestinal failure: use in stage 1 of necrotising enterocolitis (NEC)

Cited by 2 publications

References 0 publications

Assessing immunogenicity of CRISPR-NCas9 engineered strain against porcine epidemic diarrhea virus

Assessing immunogenicity of CRISPR-NCas9 engineered strain against porcine epidemic diarrhea virus

Clinical and atopic features of patients with primary eosinophilic colitis: an Italian multicentre study

Contact Info

Product

Resources

About